Search
Connect Biopharma Holdings Ltd
CNTBAdd to Watchlist
2.460USD
+0.070+2.93%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
154.27MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.93%
5 Days
+12.33%
1 Month
+6.96%
6 Months
-2.38%
Year to Date
-12.77%
1 Year
+110.38%
Key Figures
2.390Open
2.500High
446.79KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.71%Turnover Ratio
2.390Prev. Close
2.350Low
840.47KTurnover
LossP/E Static
3.62P/B
0.00%Div Yield TTM
-84.59%ROA
3.82052wk High
0.87Volume Ratio
-15.63MNet Profit
62.71MShares
-1.1542EPS TTM
-0.22Beta
-102.94%ROE
0.73052wk Low
6.28%Amplitude
100.00%Gross Margin
154.27MMarket Cap
0.62Reward/Risk
6.26%Risk Rate
TradingKey Stock Score of Connect Biopharma Holdings Ltd
Currency: USD Updated: 2026-07-02Key Insights
Connect Biopharma Holdings Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 140 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Connect Biopharma Holdings Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Connect Biopharma Holdings Ltd Highlights
StrengthsRisks
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.00K.
Fairly Valued
The company’s latest PE is -2.13, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 29.94M shares, increasing 21.31% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 21.58K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.07.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.000
Target Price
+192.89%
Upside Space
Connect Biopharma Holdings Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Connect Biopharma Holdings Ltd Info
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Ticker SymbolCNTB
CompanyConnect Biopharma Holdings Ltd
CEOQuart (Barry D)
Websitehttps://www.connectbiopharm.com
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Connect Biopharma Holdings Ltd (CNTB)?
The current price of Connect Biopharma Holdings Ltd (CNTB) is 2.46.
What is the symbol of Connect Biopharma Holdings Ltd?
The ticker symbol of Connect Biopharma Holdings Ltd is CNTB.
What is the 52-week high of Connect Biopharma Holdings Ltd?
The 52-week high of Connect Biopharma Holdings Ltd is 3.82.
What is the 52-week low of Connect Biopharma Holdings Ltd?
The 52-week low of Connect Biopharma Holdings Ltd is 0.73.
What is the market capitalization of Connect Biopharma Holdings Ltd?
The market capitalization of Connect Biopharma Holdings Ltd is 154.27M.
Is Connect Biopharma Holdings Ltd (CNTB) currently rated as Buy, Hold, or Sell?
According to analysts, Connect Biopharma Holdings Ltd (CNTB) has an overall rating of Buy, with a price target of 7.00.
What is the Earnings Per Share (EPS TTM) of Connect Biopharma Holdings Ltd (CNTB)?
The Earnings Per Share (EPS TTM) of Connect Biopharma Holdings Ltd (CNTB) is -1.00.